- Investors & Media
- Investors & Media
- Contact Us
Kamada management will host an investment community conference call on Monday,
February 6 at 8:30 a.m. Eastern time to discuss these results and answer questions.
Kamada announced today the positive Scientific Advice response from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) focused on the Company's development program in Europe for Alpha-1 Antitrypsin (G1-AAT IV) for the treatment of acute Graft-Versus-Host Disease (aGvHD) with lower gastrointestinal involvement.
Amir London, our CEO, explains in a special interview how Kamada saves lives and treats rare diseases with unique protein therapeutics.
The conpany announced today that it has signed a collaboration agreement with Yissum Research Development Company of the Hebrew University of Jerusalem, for the development of an efficient and robust eukaryotic expression system for recombinant human Alpha 1 Antitrypsin (rhAAT). The goal of this development work is to maximize protein yields and functionality.
The company announced financial results for the third quarter and nine months of 2016. Conference call will be held at Nov.10th, 8:30am Eastern Time
Kedrion Biopharma, and Kamada Ltd. (NASDAQ and TASE: KMDA) announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BL) for a human anti-rabies immunoglobulin (IgG) therapy
Kamada announced today the extension of the strategic partnership with Shire plc (LSE: SHP, NASDAQ: SHPG) for GLASSIA® .
Minimum revenue for GLASSIA in the extended agreement for the years 2017 to 2020 will reach approximately $237 million and may be expanded to $288 million during that period.
Kamada and Kedrion, collaborators on development and commercialization of post-exposure treatment for suspected rabies, announced today the filing of a BLA with the FDA. On approval by FDA, the product will represent a new option in a market where supply of post-exposure rabies treatment has been inconsistent over time. Companies planning for decision from FDA in mid-2017
Company's inhaled AAT demonstrated significant increase in endothelial lining fluid inhibitory capacity. Study results also showed that inhaled aat is the most efficient way of delivering therapeutic amounts of AAT to the primary sites of potential lung injury. Kamada to utilize results to design pivotal U.S.. study and support responses to European Medicines Agency (EMA) regarding company's Marketing Authorization Application (MAA) for inhaled AAT.